Platelet XXXX in cardiovascular disease: effect of prosthetic heart valves and cardioactive drugs on production.

@entity1 @entity1169 @entity296 @entity17732 @entity101 @entity918 @entity1242 @entity117 @entity1483 @entity4341 @entity8816 @entity1459 @entity1234 @entity3303 @entity5126 @entity4794 @entity1443 @entity1818 @entity1865 @entity1229
@entity1234 ( @entity1865 ), a product of platelet lipid peroxidation, was measured in @entity1 platelet-rich plasma. Levels of 3.19 n moles/10(9) platelets /+- 0.40 S.E. in 11 @entity1 with prosthetic heart valves were elevated (p < 0.25) compared to 17 normal subjects (2.09 /+- 0.13 n moles/10(9) platelets). Reduced production (1.44 /+- 0.28 n moles/10(9) platelets, p < 0.5) was found in 10 @entity1 with @entity1459 . Normal levels were found in @entity1 with @entity4794 , @entity296 or @entity101 . Usual serum levels of drugs used in cardiac treatment reduced @entity1865 levels as follows: @entity1443 , 47% (p < .01); @entity117 , 58% (p < .05); @entity1483 , 32.6% (p < .005), and @entity17732 , 41% (p < .05). Digoxin, @entity4341 , heparin, @entity918 , @entity3303 , @entity1242 , @entity1818 , @entity1169 , @entity5126 , or @entity1229 had no significant effect at therapeutic concentrations. None of the drugs explained the enhanced production in @entity1 with prosthetic valves while enhanced production in @entity1 with prosthetic valves while analgesic therapy could explain the decreased levels in other cardiacs. The half-time of platelet survival, measured by suppression of @entity1234 production, was 3.2 /+- 0.24 days in 9 normal subjects but could not be measured reliably in most @entity1 because of multiple drug therapies. We conclude that the blood platelets of @entity1 with prosthetic heart valves differ from those of normal subjects in their capacity to release @entity1234 after stimulation with @entity8816 . Additionally, we find that inhibition of @entity1234 production by several pharmacologic agents limits the usefulness of this method for the measurement of platelet survival in cardiac @entity1 .
